Literature DB >> 11720743

Expression of vascular endothelial growth factor (VEGF) in non-small cell lung cancer (NSCLC): association with p53 gene mutation and prognosis.

W Niklińska1, T Burzykowski, L Chyczewski, J Nikliński.   

Abstract

Vascular endothelial growth factor (VEGF) is a multifunctional cytokine that increases microvascular permeability and directly stimulates endothelial cell growth and angiogenesis. Recent evidence suggests that the genetic regulation of angiogenesis is also of crucial importance and that oncogenes and tumor suppressor genes can regulate it. The aim of this study was to determine the prognostic value of VEGF and its possible association with p53-gene mutation in 89 stage I-IIIa surgically treated NSCLC patients. DNA sequencing of the p53 gene (exons 5-8) showed 40 mutations (45%). Among the 89 NSCLC patients, immunoreactivity for VEGF was weakly, moderately and strongly positive in 35 (39%),36 (40%) and 18 (20%) cases, respectively. A strong, statistically significant association was found between the presence of a p53 gene mutation and expression of VEGF (P<0.001). The positive result of the p53 mutation increased the odds of observing a higher level of VEGF expression approximately 9.5 times (95% confidence interval: [3.44,25.89]). In the univariate analysis of survival, increasing levels of VEGF expression were associated with poor prognosis (P<0.001 for trend). In the multivariate analysis, after adjusting for the presence of a p53-gene mutation, gender, TNM stage and histological type, the prognostic effect of VEGF expression level was marginally non-significant (P=0.077). When the two-category quantification of the VEGF level was considered (low vs. intermediate/high), a marginally significant (P=0.024), unfavorable effect of intermediate/high levels of VEGF expression, independent of the effect of the presence of a p53-gene mutation, was found. In conclusion, we found that the p53 mutation was closely related to VEGF expression. Additionally, we observed that an intermediate/high expression of VEGF might be a useful indicator of prognosis in NSCLC. This latter conjecture, suggested by an analysis of the data, ought however, to be independently verified in further studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11720743     DOI: 10.1016/s0169-5002(01)00346-4

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  9 in total

1.  Maspin, VEGF and p53 expression in small biopsies of primary advanced lung cancer and relationship with clinicopathologic parameters.

Authors:  Ahmet Bircan; Sema Bircan; Nilgun Kapucuoglu; Necla Songur; Onder Ozturk; Ahmet Akkaya
Journal:  Pathol Oncol Res       Date:  2010-03-28       Impact factor: 3.201

Review 2.  Lung cancer. 9: Molecular biology of lung cancer: clinical implications.

Authors:  K M Fong; Y Sekido; A F Gazdar; J D Minna
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

3.  Repeated aerosol delivery of carboxyl-terminal modulator protein suppresses tumor in the lungs of K-rasLA1 mice.

Authors:  Soon-Kyung Hwang; Hwang-Tae Lim; Arash Minai-Tehrani; Eun-Sun Lee; Jongmin Park; Seung Bum Park; George R Beck; Myung-Haing Cho
Journal:  Am J Respir Crit Care Med       Date:  2009-03-12       Impact factor: 21.405

Review 4.  Medicinal plants and cancer chemoprevention.

Authors:  Avni G Desai; Ghulam N Qazi; Ramesh K Ganju; Mahmoud El-Tamer; Jaswant Singh; Ajit K Saxena; Yashbir S Bedi; Subhash C Taneja; Hari K Bhat
Journal:  Curr Drug Metab       Date:  2008-09       Impact factor: 3.731

5.  Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer.

Authors:  Matthew D Taylor; Philip W Smith; William K Brix; Mark R Wick; Nicholas Theodosakis; Brian R Swenson; Benjamin D Kozower; Christine L Lau; David R Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2009-01       Impact factor: 5.209

6.  Suppression of lung cancer progression by biocompatible glycerol triacrylate-spermine-mediated delivery of shAkt1.

Authors:  Seong-Ho Hong; Ji-Eun Kim; You-Kyoung Kim; Arash Minai-Tehrani; Ji-Young Shin; Bitna Kang; Hye-Joon Kim; Chong-Su Cho; Chanhee Chae; Hu-Lin Jiang; Myung-Haing Cho
Journal:  Int J Nanomedicine       Date:  2012-05-04

7.  Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1.

Authors:  S M Sagar; D Yance; R K Wong
Journal:  Curr Oncol       Date:  2006-02       Impact factor: 3.677

8.  Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer.

Authors:  Ahmed Abdallah; Mohamed Belal; Ahmed El Bastawisy; Rabab Gaafar
Journal:  Oncol Lett       Date:  2014-03-31       Impact factor: 2.967

9.  Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model.

Authors:  Ewa Maj; Beata Filip-Psurska; Magdalena Milczarek; Mateusz Psurski; Andrzej Kutner; Joanna Wietrzyk
Journal:  Int J Oncol       Date:  2017-12-15       Impact factor: 5.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.